The Federal Trade Commission on Thursday warned brand-name drug manufacturers against improperly listing patents in the U.S. Food and Drug Administration’s Orange Book and addressed the harm of “blurring” advertisements toward children. 

“We’ve all heard time and time again about how drug prices are just sky high,” FTC Chair Lina Khan said in an open meeting. “We at the FTC are fully committed to using all of our tools to combat corporate misconduct that is unlawfully inflating drug prices.” 

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]